@Article{096504022X16427607626672, AUTHOR = {Shuai Liu, Lu Lu, Feng Pan, Chunsheng Yang, Jing Liang, Jinfeng Liu, Jian Wang, Rong Shen, Fu-Ze Xin, Nan Zhang}, TITLE = {Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer}, JOURNAL = {Oncology Research}, VOLUME = {29}, YEAR = {2021}, NUMBER = {1}, PAGES = {25--31}, URL = {http://www.techscience.com/or/v29n1/48450}, ISSN = {1555-3906}, ABSTRACT = {Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the Kaplan–Meier method. The efficacy and safety of fruquintinib were also assessed. Seventy-five patients were involved in our study, and 29.3% of patients achieved stable disease (SD). Median PFS was 5.4 months (95% CI: 4.841–5.959). The treatment-emergent adverse events (TEAEs) with fruquintinib were acceptable with grade 3 TEAEs of 6%. The grade 3 TEAEs were hand–foot skin reaction (HFSR), fatigue, and stomatitis. The ECOG performance status was associated with PFS. In this real-world study, the clinical activity of fruquintinib was consistent with what has been reported in previous clinical trials. The level of safety was acceptable, and the side effects were manageable.}, DOI = {10.3727/096504022X16427607626672} }